CA125 as a serum marker for poor prognosis in ovarian malignancies

Ronald D. Alvarez, Alexander To, Larry R. Boots, Hugh M. Shingleton, Kenneth D Hatch, Judy Hubbard, Seng Jaw Soong, Mark E. Potter

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

In cancer of the ovary, a tumor marker is much needed to assist the conventional methods for monitoring the disease course. All published reports of the CA125 serum immunoassay to date have indicated that rising or falling CA125 levels correlated with disease progression or regression in patients with ovarian malignancies. Our experience with CA125 at the University of Alabama at Birmingham shows that rising CA125 levels are highly suggestive of progressive disease. However, the significance of our findings with CA125 is that, contrary to other reports, falling CA125 levels are not a reliable indicator for regressive disease. Thus, falling CA125 levels are not clinically useful whereas rising CA125 levels may be interpreted as indicative of poor tumor response to therapy, and of the presence of persistent or recurrent disease either prior to second-look laparotomy or during post-treatment follow-up.

Original languageEnglish (US)
Pages (from-to)284-289
Number of pages6
JournalGynecologic Oncology
Volume26
Issue number3
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Accidental Falls
Biomarkers
Neoplasms
Tumor Biomarkers
Immunoassay
Ovarian Neoplasms
Laparotomy
Disease Progression
Therapeutics
Serum

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Alvarez, R. D., To, A., Boots, L. R., Shingleton, H. M., Hatch, K. D., Hubbard, J., ... Potter, M. E. (1987). CA125 as a serum marker for poor prognosis in ovarian malignancies. Gynecologic Oncology, 26(3), 284-289. https://doi.org/10.1016/0090-8258(87)90019-9

CA125 as a serum marker for poor prognosis in ovarian malignancies. / Alvarez, Ronald D.; To, Alexander; Boots, Larry R.; Shingleton, Hugh M.; Hatch, Kenneth D; Hubbard, Judy; Soong, Seng Jaw; Potter, Mark E.

In: Gynecologic Oncology, Vol. 26, No. 3, 1987, p. 284-289.

Research output: Contribution to journalArticle

Alvarez, RD, To, A, Boots, LR, Shingleton, HM, Hatch, KD, Hubbard, J, Soong, SJ & Potter, ME 1987, 'CA125 as a serum marker for poor prognosis in ovarian malignancies', Gynecologic Oncology, vol. 26, no. 3, pp. 284-289. https://doi.org/10.1016/0090-8258(87)90019-9
Alvarez, Ronald D. ; To, Alexander ; Boots, Larry R. ; Shingleton, Hugh M. ; Hatch, Kenneth D ; Hubbard, Judy ; Soong, Seng Jaw ; Potter, Mark E. / CA125 as a serum marker for poor prognosis in ovarian malignancies. In: Gynecologic Oncology. 1987 ; Vol. 26, No. 3. pp. 284-289.
@article{339df79685d741869366936488bceca3,
title = "CA125 as a serum marker for poor prognosis in ovarian malignancies",
abstract = "In cancer of the ovary, a tumor marker is much needed to assist the conventional methods for monitoring the disease course. All published reports of the CA125 serum immunoassay to date have indicated that rising or falling CA125 levels correlated with disease progression or regression in patients with ovarian malignancies. Our experience with CA125 at the University of Alabama at Birmingham shows that rising CA125 levels are highly suggestive of progressive disease. However, the significance of our findings with CA125 is that, contrary to other reports, falling CA125 levels are not a reliable indicator for regressive disease. Thus, falling CA125 levels are not clinically useful whereas rising CA125 levels may be interpreted as indicative of poor tumor response to therapy, and of the presence of persistent or recurrent disease either prior to second-look laparotomy or during post-treatment follow-up.",
author = "Alvarez, {Ronald D.} and Alexander To and Boots, {Larry R.} and Shingleton, {Hugh M.} and Hatch, {Kenneth D} and Judy Hubbard and Soong, {Seng Jaw} and Potter, {Mark E.}",
year = "1987",
doi = "10.1016/0090-8258(87)90019-9",
language = "English (US)",
volume = "26",
pages = "284--289",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - CA125 as a serum marker for poor prognosis in ovarian malignancies

AU - Alvarez, Ronald D.

AU - To, Alexander

AU - Boots, Larry R.

AU - Shingleton, Hugh M.

AU - Hatch, Kenneth D

AU - Hubbard, Judy

AU - Soong, Seng Jaw

AU - Potter, Mark E.

PY - 1987

Y1 - 1987

N2 - In cancer of the ovary, a tumor marker is much needed to assist the conventional methods for monitoring the disease course. All published reports of the CA125 serum immunoassay to date have indicated that rising or falling CA125 levels correlated with disease progression or regression in patients with ovarian malignancies. Our experience with CA125 at the University of Alabama at Birmingham shows that rising CA125 levels are highly suggestive of progressive disease. However, the significance of our findings with CA125 is that, contrary to other reports, falling CA125 levels are not a reliable indicator for regressive disease. Thus, falling CA125 levels are not clinically useful whereas rising CA125 levels may be interpreted as indicative of poor tumor response to therapy, and of the presence of persistent or recurrent disease either prior to second-look laparotomy or during post-treatment follow-up.

AB - In cancer of the ovary, a tumor marker is much needed to assist the conventional methods for monitoring the disease course. All published reports of the CA125 serum immunoassay to date have indicated that rising or falling CA125 levels correlated with disease progression or regression in patients with ovarian malignancies. Our experience with CA125 at the University of Alabama at Birmingham shows that rising CA125 levels are highly suggestive of progressive disease. However, the significance of our findings with CA125 is that, contrary to other reports, falling CA125 levels are not a reliable indicator for regressive disease. Thus, falling CA125 levels are not clinically useful whereas rising CA125 levels may be interpreted as indicative of poor tumor response to therapy, and of the presence of persistent or recurrent disease either prior to second-look laparotomy or during post-treatment follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0023146533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023146533&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(87)90019-9

DO - 10.1016/0090-8258(87)90019-9

M3 - Article

C2 - 2435619

AN - SCOPUS:0023146533

VL - 26

SP - 284

EP - 289

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -